Opinion-Trading Ads: MPL Challenges ASCI White Paper, Seeks $6mil in Damages On May 23, 2025, Galactus Funware Technology Pvt Ltd, the parent company of Mobile Premier League (MPL), served an 11-page legal notice to the Advertising Standards Council of India (ASCI). The notice demands two principal remedies: (i) immediate withdrawal of ASCI’s white-paper Examining Opinion Trading […]
Introduction In KEMIN INDUSTRIES, INC. v. Controller of Patents [1]1, the Madras High Court overturned the rejection of a patent application concerning a method of improving animal feed by supplementing bacterial ferulic acid esterase (FAE) with four specific enzymes. The Patent Office had denied the application under Sections 2(1)(j), 3(d), and 3(i) of the Patents […]
Introduction On 15th March 2024, the Indian Patent Office (IPO) published the Patent (Amendment) Rules, 2024. Notably, Rules 137 and 138—relating to the Controller’s powers to condone procedural irregularities and extend deadlines were significantly amended. These changes clarify which specific irregularities can now be condoned by the Controller and which deadlines are eligible for extension. […]
Introduction On May 27, 2025, in Zeria Pharmaceutical Co. Ltd. v. Deputy Controller of Patents and Designs1, the Delhi High Court upheld the refusal of divisional patent, affirming that minor structural modifications of known pharmaceutical compounds—especially intermediates—must still demonstrate enhanced therapeutic efficacy to be patentable under Section 3(d) of the Indian Patents Act, 1970. The […]
Introduction On June 10, 2025, in TikTok Limited v. Registrar of Trade Marks , the Bombay High Court made a significant ruling, backing the Registrar of Trade Marks’ decision to deny the registered mark “TikTok” the status of a “well-known mark” under Indian Trademark Act. The court’s decision to uphold this refusal is particularly noteworthy […]
Introduction On March 25, 2025, the Delhi High Court denied the request of F. Hoffmann-La Roche AG for an interim injunction against Natco Pharma in a high-stakes pharmaceutical patent dispute in F. Hoffmann-La Roche Ag & Anr. vs Natco Pharma Limited [1]1. At issue was Roche’s species patent on “Risdiplam,” a life-saving drug for Spinal […]